Shanghai GeBaiDe Biotechnical

Shanghai Gebaide Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing innovative CAR-T cell therapies for the treatment of solid tumors. Founded in 2021 and based in Shanghai, the company utilizes its proprietary technology platform to engineer T-cells that can effectively penetrate and persist within the immunosuppressive tumor microenvironment. Its lead candidate, G-001, is a CAR-T therapy targeting Claudin 18.2, currently being evaluated in Phase 1 clinical trials for patients with advanced gastric and pancreatic cancers. Gebaide is backed by prominent investors such as Matrix Partners China and Decheng Capital, reflecting its potential in the competitive cell therapy landscape. The company's mission is to provide transformative treatment options for cancer patients by overcoming the historical limitations of cell therapy in solid malignancies.